About Me

At University College London (UCL), my PhD research tackles complex challenges in drug discovery and generative modelling. I have actively contributed to identifying hits for MurD Ligase and mapped binding sites for SARS-CoV-2 (nsp13 and nsp3) utilizing 3D interaction fingerprints. My collaborative research also extended to materials discovery, where I worked on quantum chemistry computations for perovskite photovoltaics. Beyond my own research, I have co-supervised over 10 MSc theses and served as a Teaching Assistant for Bayesian Deep Learning Methods at UCL.

I am equally committed to translating research into real-world applications and have consistently bridged the gap between academia and industry. Most recently, as an ML Research Scientist at Matterhorn Studio, I executed advanced Bayesian optimization projects in direct collaboration with Novo Nordisk. Prior to this, I served as the ML Technical Lead at London North Eastern Railway (LNER), where I designed an ISO27007-compliant AWS MLOps infrastructure and managed a technical team to deploy production-ready AI models. My first hands-on drug discovery experience started as ML R&D Consultant for April19 Discovery, where I specialized in molecular drug design for the central nervous system using generative models and multi-task DNNs.

If we zoom out, my background is quite diverse! I have over 15 years of experience across tech, research, and finance. Previously, I led the Data Science team at Fractal Labs, where we built a full production pipeline using TensorFlow Extended and secured a £300k InnovateUK grant. Before making the jump into machine learning, I built a strong foundation in applied mathematical modeling through visiting research engagements at Imperial College London, Columbia University, and the Oxford-Man Institute. I originally began my career spending several years in quantitative finance, pricing exotic financial derivatives at KBC Global Services and consulting for PwC.

When I step away from the research and mathematical modelling, my pursuits get a bit more unconventional. I am the creator behind an artistic project best described as a multi-species, multicultural alter ego. I cannot reveal my artistic identity publicly—Banksy already has the anonymous artist market cornered!—but figuring out how to successfully sell the work while juggling a constant stream of new ideas is a fascinating exploration all its own. I am also planning to merge my creative side with my deep appreciation for canine intelligence; I am currently designing art classes specifically for dogs, which I hope to launch later this year.

Last updated 2026-02-09